Breaking Five Men Arrested Near RAF Fairford on Suspicion of Terror Offenses 300-Year-Old Mexican Musical Tradition ‘Fandango’ Sees Resurgence in Global Interest Lung Cancer Patient and Professor Shares Journey to Highlight Treatment Advancements Nursing Homes Increasingly Serve As Last Resort For Individuals Lacking Housing Options Trump Administration Plans $810 Million Funding Cut Through ‘Pocket Rescission’, Drawing Criticism
Sunday September 27, 2026
64° Baltimore, MD
Become a Contributor
Section

Business

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
Press Release

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026

Innovent Biologics · 18 minutes ago
Read Full Story